Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent

NCT ID: NCT00544609

Last Updated: 2014-10-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-12-31
• Study Completion Date: 2012-05-31

Brief Summary

Safety profile and to determine maximum tolerated dose of Sorafenib in combination with Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent

Detailed Description

Study phase I in patients with Invasive Bladder Cancer

Conditions

Bladder Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sorafenib

2 weeks:Sorafenib, 6 weeks and a half:Sorafenib with radiotherapy, 4 weeks:Sorafenib

Group Type: OTHER

Sorafenib

Intervention Type: DRUG

Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day

Radiotherapy

Intervention Type: PROCEDURE

3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2

Interventions

Sorafenib

Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day

Intervention Type: DRUG

Radiotherapy

3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2

Intervention Type: PROCEDURE

Other Intervention Names

Nexavar; Sorafenib; Nexavar

Eligibility Criteria

Inclusion Criteria

• Patients diagnosed with urothelial carcinoma of the bladder, in clinical stages T2-4a N0 M0 (if multifocal evaluation of all lesions by biopsies), who are not candidates for radical cystectomy by medical reasons or refusal.
• No prior treatment with radiotherapy to the bladder or systemic chemotherapy.
• Patients must be ≥ 18 years old.
• Patients must have ECOG performance status 0 to 2.
• Life expectancy of at least 12 weeks.
• Patients with adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:

hemoglobin ≥ 9.0 g/dl absolute neutrophil count ≥ 1.500/mm3 platelets ≥ 100.000/mm3. total bilirubin ≤ 1.5 times the upper limit of normality SGOT (AST) and/or SGPT (ALT) ≤ 2.5 times the upper limit of normality alkaline phosphatase ≤ 4 x ULN serum creatinine ≤1.5 upper limit of normality PT-INR/PTT < 1.5 x upper limit of normality creatinine clearance ≥ 40 ml/min using Cockcroft-Gaul

• Patients must give their written informed consent before any procedure related to the study is performed; therefore, it must be given at the selection visit. The patient must be informed that he has the right to withdraw from the study at any time, without any kind of prejudice.
• Patients who are capable of accomplishing the study's requirements and without any impediments to follow the instructions.
• Women of fertile age must have a negative result in the pregnancy test performed 7 days before the beginning of the administration of the study medication.
• Patients from both sexes must use adequate contraceptive methods (oral or injectable contraceptives, intrauterine device, condom, sterilization) whilst participating in the protocol. After the retreat of treatment with sorafenib, the contraceptive methods must be used during 4 weeks in women and during 3 months in men.

Exclusion Criteria

• Patients with active infection or other serious medical conditions (autologous bone marrow transplant or stem cell rescue within 4 months of study, patients undergoing renal dialysis, known HIV infection or chronic hepatitis B or C, active clinically serious infections > CTCAE Grade 2, non-healing wound, ulcer, or bone fracture).
• Abuse of substances, clinical conditions, psychological or social, that would preclude appropriate informed consent or compliance with protocol.
• Concurrent treatment with other experimental drugs (within 30 days prior to study entry).
• Concurrent treatment with other anti-cancer- or immunotherapy during the study or within 4 weeks of study entry.
• Treatment wuth mitomycin C or nitrosureas during 6 weeks prior of study entry.
• History of prior malignancies within the preceding 5 years other than previously treated basal cell carcinoma of the skin, incipient prostate cancer and in situ cervix carcinoma.
• Pregnant or breast feeding patients.
• Known or suspected allergy to sorafenib.
• Cardiac disease: Congestive heart failure > class II NYHA; active CAD (myocardial infarction more than 6 months to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (beta blockers or digoxin are permitted).
• Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management.
• Known brain metastasis. Patients with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis.
• Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months.
• Patients with hydronephrosis.
• Patients with seizure disorder requiring medication (such as steroids or antiepileptics).
• History of organ allograft.
• Patient unable to swallow oral medication.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Spanish Oncology Genito-Urinary Group

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xavier García del Muro Solans, MD

Role: STUDY_CHAIR

Institut Català d' Oncología, Barcelona

Salvador Villà Freixa, MD

Role: STUDY_CHAIR

Institut Català d' Oncología, Barcelona

Locations

Hospital Clínic i Provincial de Barcelona

Barcelona, , Spain

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Institut Català d' Oncología

Barcelona, , Spain

Countries

Spain

Other Identifiers

SOGUG-07-01

Identifier Type: -

Identifier Source: org_study_id